Welcome to our dedicated page for Enveric Biosciences SEC filings (Ticker: ENVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Enveric Biosciences, Inc. (NASDAQ: ENVB) SEC filings page on Stock Titan centralizes the company’s regulatory disclosures from the U.S. Securities and Exchange Commission. Enveric is a biotechnology company focused on small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders, and its filings provide detailed information on financing transactions, listing status, governance matters, and risk factors as described by the company.
Investors researching ENVB can use this page to access current reports on Form 8‑K, which Enveric has filed in connection with warrant exercise inducement agreements, private placements of new warrant series, and related use of proceeds for product development, working capital, and general corporate purposes. Other 8‑K filings address Nasdaq listing qualifications, including notices regarding stockholders’ equity requirements, minimum bid price deficiencies, and the implementation of a 1‑for‑12 reverse stock split approved by stockholders and effected through a certificate of amendment.
The filings feed also includes proxy materials such as the definitive proxy statement on Schedule DEF 14A, where Enveric outlines proposals for stockholder approval. These have included authorizations for share issuances related to warrants, reverse stock split ranges, and increases in authorized common stock. Voting results for special meetings and annual meetings are reported in subsequent 8‑K filings, giving readers transparency into stockholder decisions.
Through periodic reports referenced in Enveric’s press releases, such as its Annual Report on Form 10‑K and Quarterly Reports on Form 10‑Q, the company discusses its business, pipeline, patent estate, financial condition, and risk factors. On Stock Titan, users can quickly locate these documents and use AI-powered summaries to interpret complex sections, including descriptions of EB‑003 and other neuroplastogenic programs, capital structure details, and discussions of Nasdaq compliance.
In addition, this page provides access to information about unregistered sales of equity securities, warrant terms, and changes to the company’s charter reported in SEC filings. AI-generated highlights help readers identify key terms—such as exercise prices, expiration dates, and conditions for new warrant series—without manually parsing every exhibit. For those tracking ENVB, the SEC filings page offers a structured way to review how Enveric presents its strategy, financing activities, and governance actions in official regulatory documents.
Enveric Biosciences, Inc. is soliciting proxies for its 2026 virtual Annual Meeting of Stockholders to be held via webcast. The board asks stockholders to vote on electing six directors and on proposals that include an extension to effect a reverse stock split at ratios between 1-for-5 and 1-for-50 and an extension to increase authorized common stock from 100,000,000 to 5,000,000,000 shares. Other proposals include advisory approval of executive compensation, ratification of CBIZ CPAs P.C. as auditor, and an adjournment proposal.
Enveric Biosciences is a Delaware-based biotechnology company developing next‑generation, non‑hallucinogenic neuroplastogenic drugs for psychiatric and neurological disorders. Its lead candidate, EB‑003, a DMT‑derived compound from the EVM301 Series, is in preclinical development with IND‑enabling studies planned.
The company also maintains a large psychedelic‑inspired IP library (Psybrary™) and has out‑licensed certain cannabinoid and psychedelic assets. As of June 30, 2025, non‑affiliate equity value was about $3.6 million, and the auditor has raised substantial doubt about Enveric’s ability to continue as a going concern due to recurring losses and funding needs.
Enveric Biosciences reported a net loss attributable to stockholders of $4.0 million for the quarter ended December 31, 2025, compared with a net loss of $3.2 million a year earlier. Basic and diluted loss per share was $6.12 for the quarter. The company ended 2025 with $4.7 million in cash and raised gross proceeds of $12.2 million during the year through offerings, including $4.9 million in the fourth quarter.
Subsequently, Enveric raised about $1.5 million in a registered direct offering in January 2026 and approximately $1.45 million via an at-the-market offering in February 2026. Operationally, the company advanced its lead candidate EB-003, a non-hallucinogenic neuroplastogen, by completing pre-IND dose range finding studies, achieving key manufacturing milestones, and receiving FDA feedback allowing streamlined plans for an IND submission ahead of a planned first-in-human Phase 1 trial. Enveric also strengthened its intellectual property around the EVM301 and EVM401 compound series, executed licensing agreements for cannabinoid-COX-2 conjugates, expanded a topical cannabinoid collaboration, and completed a 1-for-12 reverse stock split while relocating its headquarters to Cambridge, Massachusetts.
Enveric Biosciences filed a prospectus registering 680,620 shares of Common Stock. The registration covers up to 328,802 shares issuable upon exercise of Series G Warrants, up to 328,802 shares issuable upon exercise of Series H Warrants, and 23,016 shares issuable upon exercise of Placement Agent Warrants.
The prospectus states the Company will not receive proceeds from sales by the Selling Stockholders, but will receive net proceeds if the January 2026 Warrants are exercised for cash. The exercise prices are $4.16 for the Series G and H Warrants and $5.5125 for the Placement Agent Warrants. The document cites 1,390,335 shares outstanding as of February 4, 2026 and an assumed post‑exercise outstanding share count of 2,070,955 if all January 2026 Warrants are exercised. The prospectus notes a last reported Nasdaq sale price of $2.84 on February 4, 2026.
Enveric Biosciences, Inc. has filed an S-1 registering 680,620 shares of common stock underlying January 2026 warrants, including Series G, Series H and placement agent warrants issued in connection with a January 2026 registered direct offering and concurrent private placement.
The filing covers issuance of shares upon warrant exercise and their resale by selling stockholders. Enveric will not receive proceeds from stockholder resales, but would receive cash if the warrants are exercised at $4.16 per share for the Series G and H warrants and $5.5125 per share for the placement agent warrants, planned for product development, working capital and general corporate purposes.
The company focuses on non-hallucinogenic, neuroplastogenic small-molecule therapies, led by EB-003, and highlights significant risks, including substantial liquidity needs, going concern uncertainty, dependence on early-stage drug candidates, future dilution from equity financings and warrants, and high volatility in its Nasdaq-listed ENVB shares.
Enveric Biosciences, Inc. filed an 8-K describing that it has filed a prospectus supplement to register an additional $1,346,000 of shares of its common stock issuable under its existing At The Market Offering Agreement with H.C. Wainwright & Co., LLC.
The Agreement was originally dated April 9, 2025, and Enveric has previously sold an aggregate of $1,853,878.34 of common stock through the sales agent under this arrangement. A legal opinion from Greenberg Traurig, LLP regarding the validity of the newly registered shares is included as Exhibit 5.1, with a related consent in Exhibit 23.1.
Enveric Biosciences, Inc. is launching an at-the-market stock offering of up to $1,346,000 of common stock under its existing $200 million shelf registration. The company has entered into an agreement with H.C. Wainwright & Co., which will act as sales agent.
Shares may be sold from time to time on Nasdaq or other markets at prevailing prices, with Wainwright earning a 3.0% fee on gross proceeds. If shares were sold at $2.84, the recent Nasdaq price, common stock outstanding could increase from 1,390,335 to about 1,864,278 shares.
Enveric plans to use any net proceeds primarily to develop its lead drug candidate EB-003, a non-hallucinogenic neuroplastogenic compound for difficult mental health disorders, and for general corporate purposes such as research and development, working capital, possible debt reduction, acquisitions and capital expenditures. The filing highlights risks including potential share price pressure from additional stock sales, dilution from equity and warrant overhang, and the company’s need for ongoing access to capital within Form S-3 public float limits.
Enveric Biosciences, Inc. received a Schedule 13G reporting a new significant passive holder. Lind Global Fund III LP, together with Lind Global Partners III LLC and Jeff Easton, reports beneficial ownership of 141,265 shares of common stock, equal to 9.99% of the class as of 01/28/2026.
The position consists of 79,366 common shares plus 79,366 Series G warrants and 79,366 Series H warrants, all subject to a 9.99% beneficial ownership limitation that caps how many warrant shares can be converted at any time. The reporting persons certify the holdings are not for the purpose of changing or influencing control of Enveric.
Enveric Biosciences, Inc. has a group of investors led by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC reporting a passive stake in its common stock. As of the close of business on February 2, 2026, they may be deemed to beneficially own 71,246 shares, representing about 4.99% of the company’s common stock.
The holding includes 33,800 common shares and 37,446 shares issuable upon exercise of one warrant, while additional warrants are subject to 4.99% “blocker” provisions that limit further exercises. The investors certify the position was not acquired to change or influence control of Enveric Biosciences.